BEGIN:VCALENDAR
X-WR-TIMEZONE:Europe/LondonVERSION:2.0
PRODID:-//University of Liverpool//University Events//EN
BEGIN:VEVENT
UID:20260513T160017-83538-UniversityOfLiverpool
DTSTAMP:20260513T160017
DTSTART:20160923T124500
DTEND:20160923T134500
LOCATION:William Henry Duncan Building, Apex Building, 6 West Derby Street, Liverpool L7 7EA
SUMMARY:Use of selenium in the design of medical devices and anti-cancer, anti-microbial and anti-viral drugs 
DESCRIPTION:Dr. Ted Reid received his Bachelors in Chemistry from Occidental College and his Masters in Chemistry from the University of Arizona working in Natural Products Chemistry.  He then received his Doctorate in Chemistry/Biochemistry from the University of California, Los Angeles, working on the mechanism of action of Pepsin.  This was followed by postdoctoral studies with Irwin Wilson at the University of Colorado on the mechanism of action of alkaline phosphatase.  He then moved to a faculty position at Yale University, for 14 years, in the Departments of Molecular Biophysics and Biochemistry and the Ophthalmology and Visual Science.  His work at Yale was on ocular tumors and tumor viruses.  In 1984 he joined the faculty of the University of California, Davis, where his laboratory worked on defense peptides and neuropeptides in ocular wound healing.  In 1990 he moved to the Texas Tech University Health Sciences Center where he is the Director of the Biotechnology Program and Vice Chairman of Ophthalmology.  His research currently concerns wound healing, drug design and the use of organo-selenium compounds to combat biofilms and bacterial infection.
END:VEVENT
END:VCALENDAR